{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-002750","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.510289+00:00","generated_at":"2026-05-23T20:39:39.976356+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GT Biopharma issues pre-funded warrant to Cytovance for 326,251 shares as service consideration","bullets":["Issued pre-funded warrant to purchase up to 326,251 shares of common stock at $0.0001 per share.","Aggregate exercise price of $846,562.50 was pre-funded via services rendered by Cytovance Biologics.","Warrant is immediately exercisable with a beneficial ownership limitation; no cash received.","Issued without registration under Section 4(a)(2) of Securities Act as a private transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-002750","json":"https://secwatch.observer/filing/0001641172-25-002750.json","markdown":"https://secwatch.observer/filing/0001641172-25-002750.md","text":"https://secwatch.observer/filing/0001641172-25-002750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000164117225002750/0001641172-25-002750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000164117225002750/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T20:39:39.976356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}